-
Something wrong with this record ?
Serum neurofilament light chain in response to probiotics in bi-center, double-blind, randomized, placebo-controlled clinical trial (CleverAge Biota)
L. Fialova, A. Bartos, M. Kalousova, L. Noskova, M. Zelenkova, M. Slukova, T. Zima
Language English Country Czech Republic
Document type Journal Article, Randomized Controlled Trial, Multicenter Study
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
PubMed
39410847
DOI
10.5507/bp.2024.032
Knihovny.cz E-resources
- MeSH
- Biomarkers blood MeSH
- Double-Blind Method MeSH
- Middle Aged MeSH
- Humans MeSH
- Neurofilament Proteins * blood MeSH
- Probiotics * therapeutic use MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Gastrointestinal Microbiome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
BACKGROUND AND AIMS: Neurodegenerative disorders affecting the brain and spinal cord are caused by a large number of factors. More recently, imbalances in gut microbiota are found to be one factor linked directly to neurological dysfunction. Probiotics prevent cognitive decline. For the first time, the effect of probiotics was assessed by monitoring the concentrations of the neurodegeneration biomarker neurofilament light chains (NfL) in a well-defined group of community-dwelling individuals. The aim of this study was to determine whether administration of our new probiotics could reduce NfL concentrations. METHODS: The serum NfL concentrations were measured in total of 190 serum samples of 85 older community-dwelling individuals. The participants were randomly divided into two groups: the PROPLA group and the PLAPRO group. Individuals in the PROPLA group started with a three-month use of probiotics and continued with a three-month use of placebo while the order was reversed in the PLAPRO group. The participants underwent detailed examinations at three time points: at baseline, in three and six months. The serum NfL concentrations were determined using ultrasensitive single-molecule array (SIMOA) assay. RESULTS: Longitudinal comparisons of NfL concentrations between samplings at different time points in the PROPLA and PLAPRO groups showed no statistically significant differences. Baseline NfL concentrations at the beginning of the study and in the succeeding samplings were not significantly different for the two groups in cross-sectional comparisons. CONCLUSIONS: Serum NfL concentrations were not influenced by the three-month use of probiotics.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25017844
- 003
- CZ-PrNML
- 005
- 20250916141442.0
- 007
- ta
- 008
- 250814s2025 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2024.032 $2 doi
- 035 __
- $a (PubMed)39410847
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Fialová, Lenka, $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia $d 1957- $7 xx0074272
- 245 10
- $a Serum neurofilament light chain in response to probiotics in bi-center, double-blind, randomized, placebo-controlled clinical trial (CleverAge Biota) / $c L. Fialova, A. Bartos, M. Kalousova, L. Noskova, M. Zelenkova, M. Slukova, T. Zima
- 520 9_
- $a BACKGROUND AND AIMS: Neurodegenerative disorders affecting the brain and spinal cord are caused by a large number of factors. More recently, imbalances in gut microbiota are found to be one factor linked directly to neurological dysfunction. Probiotics prevent cognitive decline. For the first time, the effect of probiotics was assessed by monitoring the concentrations of the neurodegeneration biomarker neurofilament light chains (NfL) in a well-defined group of community-dwelling individuals. The aim of this study was to determine whether administration of our new probiotics could reduce NfL concentrations. METHODS: The serum NfL concentrations were measured in total of 190 serum samples of 85 older community-dwelling individuals. The participants were randomly divided into two groups: the PROPLA group and the PLAPRO group. Individuals in the PROPLA group started with a three-month use of probiotics and continued with a three-month use of placebo while the order was reversed in the PLAPRO group. The participants underwent detailed examinations at three time points: at baseline, in three and six months. The serum NfL concentrations were determined using ultrasensitive single-molecule array (SIMOA) assay. RESULTS: Longitudinal comparisons of NfL concentrations between samplings at different time points in the PROPLA and PLAPRO groups showed no statistically significant differences. Baseline NfL concentrations at the beginning of the study and in the succeeding samplings were not significantly different for the two groups in cross-sectional comparisons. CONCLUSIONS: Serum NfL concentrations were not influenced by the three-month use of probiotics.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a probiotika $x terapeutické užití $7 D019936
- 650 12
- $a neurofilamentové proteiny $x krev $7 D016900
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a střevní mikroflóra $7 D000069196
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a lidé středního věku $7 D008875
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Bartoš, Aleš $u Department of Neurology, Third Faculty of Medicine, Charles University, Faculty Hospital Kralovske Vinohrady, Prague, Czechia $7 xx0028753
- 700 1_
- $a Kalousová, Marta, $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia $d 1974- $7 mzk2005318016
- 700 1_
- $a Nosková, Libuše $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia $7 xx0224705
- 700 1_
- $a Zelenková, Miroslava $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia $7 xx0302395
- 700 1_
- $a Slukova, Michaela $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia
- 700 1_
- $a Zima, Tomáš, $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia $d 1966- $7 jn20000620440
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 169, č. 2 (2025), s. 91-97
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39410847 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y p $z 0
- 990 __
- $a 20250814 $b ABA008
- 991 __
- $a 20250916141430 $b ABA008
- 999 __
- $a ok $b bmc $g 2394218 $s 1255974
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 169 $c 2 $d 91-97 $e 20241014 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $n Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub $x MED00012606
- LZP __
- $b NLK191 $a Pubmed-20250814